PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP OBTAINS CANNABIS RESEARCH LICENSE FROM HEALTH CANADA. QUEBEC, October 3, 2019 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical...
Press Releases
Devonian Health Group Announces the Formation of a Clinical Dermatology Advisory Board with mandate to assist in the development of Cannabinoids-based pharmaceutical products
PRESS RELEASE For immediate release Devonian Health Group Announces the Formation of a Clinical Dermatology Advisory Board with mandate to assist in the development of Cannabinoids-based pharmaceutical products. QUEBEC, September 4, 2019 – Devonian Health Group...
Devonian Health Group announces the publication of positive results of the Purgenesis® Anti-aging Care clinical study in the Journal of Cosmetic Dermatology
PRESS RELEASE For immediate release Devonian Health Group announces the publication of positive results of the Purgenesis® Anti-aging Care clinical study in the Journal of Cosmetic Dermatology. QUEBEC, August 28, 2019 – Devonian Health Group Inc. (“Devonian” or...
DEVONIAN ANNOUNCES THE CLOSING OF A $315,000 PRIVATE PLACEMENT AND AN ADDITIONAL LOAN OF $500,000
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE CLOSING OF A $315,000 PRIVATE PLACEMENT AND AN ADDITIONAL LOAN OF $500,000 QUEBEC, Québec – August 21, 2019 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD) is pleased to...
Dr George G. Zhanel joins Devonian’s Cannabinoids Scientific Advisory board
PRESS RELEASE For immediate release Dr George G. Zhanel joins Devonian’s Cannabinoids Scientific Advisory board. Quebec – July 23, 2019 – Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXv: GSD), a clinical stage biopharmaceutical corporation...
Devonian Announces the Filing of a New Patent Application related to use of Thylakoids as delivery system for Cannabinoïds and other Liposoluble Molecules
PRESS RELEASE For immediate release Devonian Announces the Filing of a New Patent Application related to use of Thylakoids as delivery system for Cannabinoïds and other Liposoluble Molecules. Quebec – June 5, 2019 – Devonian Health Group Inc. (“Devonian” or the...
Devonian signs a Binding Letter of Intent with Histapharm Inc. to extract and manufacture their proprietary botanical pharmaceutical product and to enter into a Strategic Partnership for the development of New Products
PRESS RELEASE For immediate release Devonian signs a Binding Letter of Intent with Histapharm Inc. to extract and manufacture their proprietary botanical pharmaceutical product and to enter into a Strategic Partnership for the development of New Products. ...
Devonian Health Group Announces the Formation of a Scientific Advisory Board with mandate to assist in the development of Cannabinoïds-based pharmaceutical products
PRESS RELEASE For immediate release Devonian Health Group Announces the Formation of a Scientific Advisory Board with mandate to assist in the development of Cannabinoïds-based pharmaceutical products. QUEBEC, April 10, 2019 – Devonian Health Group Inc....
Devonian Health Group announces the publication of results of in vitro assessment of the antioxidant and UV protection properties of thylakoid extracts in Journal of Cosmetic Dermatology
PRESS RELEASE For immediate release Devonian Health Group announces the publication of results of in vitro assessment of the antioxidant and UV protection properties of thylakoid extracts in Journal of Cosmetic Dermatology. QUEBEC, April 8, 2019 – Devonian...
Devonian Healthcare Group Reports Key Financial Results for Quarter Ended January 31, 2019
PRESS RELEASE For immediate release Devonian Healthcare Group Reports Key Financial Results for Quarter Ended January 31, 2019 Quebec, Quebec – April 2, 2019 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...